Clinical Trials Browser

Interventional × Hsp90 inhibitor KU757 × 30 days × Clear all

NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Active not recruiting

Melanoma, Skin Neoplasms